Advertisement

Neuroscience and Behavioral Physiology

, Volume 45, Issue 4, pp 393–397 | Cite as

Efficacy of Agomelatine in Depressive Disorders with Anxiety

  • A. A. Pribytkov
  • N. B. Panova
  • Yu. V. Popova
  • K. G. Emtsov
Article
  • 58 Downloads

An open six-week study of the efficacy of agomelatine was performed in 35 patients with single depressive episodes or recurrent depression (ICD-10 diagnoses) and clinically severe anxiety. Agomelatine was found to be highly effective and safe in the treatment of mild and moderate depression combined with anxiety disorders. Decreases in the severity of the symptoms of depression and sleep disorders were seen from treatment week 1, with reductions in anxiety from treatment week 2. By the end of the study, therapeutic effects were seen in 71.9% of patients and the remission criteria were achieved in 68.8% of patients.

Keywords

depression anxiety agomelatine sleep disorders 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O. P. Vertogradova, “Possible approaches to the typology of depression,” in: Depression (psychopathology, pathogenesis), Moscow (1980), pp. 9–15.Google Scholar
  2. 2.
    V. N. Krasnov, Affective Spectrum Disorders, Moscow (2011), pp. 146–156.Google Scholar
  3. 3.
    S. N. Mosolov, E. G. Kostyukova, A. V. Gorodinchev, et al., “Efficacy and tolerance of agomelatine in depressive states,” 15, 15–24 (2011).Google Scholar
  4. 4.
    A. A. Pribytkov, “Comparative analysis of the antidepressant activity and effects on sleep disorders of agomelatine (Valdoxan) and fluvoxamine (Fevarin),” Obozr. Psikhiatr. Med. Psikhol. im. Bekhtereva, No. 4, 38–40 (2010).Google Scholar
  5. 5.
    L. B. Allen, K. S. White, and D. H. Barlow, “Cognitive behavior therapy (CBT) for panic disorder: relationship of anxiety and depression comorbidity with treatment outcomes,” J. Psychopathol. Behav. Assess., 32, No. 2, 185–192 (2010).CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    D. S. Baldwin, C. Allgulander, B. Bandelow, et al., “An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder,” World J. Biol. Psychiatry, 13, No. 7, 510–516 (2012).CrossRefPubMedGoogle Scholar
  7. 7.
    B. Bandelow, J. Zohar, E. Hollander, et al., “World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision,” World J. Biol. Psychiatry, 9, No. 4, 248–312 (2008).CrossRefPubMedGoogle Scholar
  8. 8.
    D. H. Barlow and L. A. Campbell, “Mixed anxiety-depression and its implications for models of mood and anxiety disorders,” Comp. Psychiatry, 41, No. 2, 55–60 (2000).CrossRefGoogle Scholar
  9. 9.
    J. Das-Munshi, D. Goldberg, P. Bebbington, et al., “Public health significance of mixed anxiety and depression: beyond current classification,” Brit. J. Psychiatry, 192, No. 3, 171–177 (2008).CrossRefGoogle Scholar
  10. 10.
    J. R. Davidson, “First-line pharmacotherapy approaches for generalized anxiety disorder,” J. Clin. Psychiatry, 70, No. 2, 25–31 (2009).CrossRefPubMedGoogle Scholar
  11. 11.
    D. R. Dolnak, “Treating patients for comorbid depression, anxiety disorders, and somatic illnesses,” J. Am. Osteopath. Assoc., No. 2, 1–8 (2006).Google Scholar
  12. 12.
    E. Driessen and S. D. Hollon, “Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators,” Psychiatr. Clin. North Am., 33, No. 3, 537–555 (2010).CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    P. S. Foroushani, J. Schneider, and N. Assareh, “Meta-review of the effectiveness of computerized CBT in treating depression,” BMC Psychiatry , No. 11, 131 (2011).Google Scholar
  14. 14.
    G. Gartlehner, R. A. Hansen, and L. C. Morgan, et al., “Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis,” Ann. Intern. Med., 155, No. 11, 772–785 (2011).CrossRefPubMedGoogle Scholar
  15. 15.
    A. Hale, R. M. Corral, C. Mencacci, et al., “Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study,” Int. Clin. Psychopharmacol., 25, No. 6, 305–314 (2010).CrossRefPubMedGoogle Scholar
  16. 16.
    S. G. Hofman and J. A. Smits, “Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials,” J. Clin. Psychiatry, 69, No. 4, 621–632 (2008).CrossRefGoogle Scholar
  17. 17.
    H. E. Hollander, “Antidepressants in the treatment of depression: the clinician and the controversy,” Am. J. Clin. Hypn., 55, No. 3, 230–235 (2013).CrossRefPubMedGoogle Scholar
  18. 18.
    S. Kasper, G. Hajak, K. Wulff, et al., “Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline,” J. Clin. Psychiatry, 71, No. 2, 109–120 (2010).CrossRefPubMedGoogle Scholar
  19. 19.
    S. H. Kennedy, S. Rizvi, K. Fulton, et al., “A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR,” J. Clin. Psychopharmacol., 28, No. 3, 329–333 (2008).CrossRefPubMedGoogle Scholar
  20. 20.
    S. H. Kennedy and E. Emsley, “Placebo-controlled trial of agomelatine in the treatment of major depressive disorder,” Eur. Neuropsychopharmacol., 16, No. 2, 93–100 (2006).CrossRefPubMedGoogle Scholar
  21. 21.
    R. J. Kuzel, “Treating comorbid depression and anxiety,” J. Fam. Pract., 43, 45–53 (1996).Google Scholar
  22. 22.
    P. Lemoine, C. Guilleminault, and E. Alvarez, “Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine,” J. Clin. Psychiatry, 68, No. 11, 1723–1732 (2007).CrossRefPubMedGoogle Scholar
  23. 23.
    M. N. Levitan, M. Papelbaum, and A. E. Nardi, “A review of preliminary observations on agomelatine in the treatment of anxiety disorders,” Exp. Clin. Psychopharmacol., 20, No. 6, 504–509 (2012).CrossRefPubMedGoogle Scholar
  24. 24.
    H. Lôo, A. Hale, and H. D’haenen, “Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study,” Int. Clin. Psychopharmacol., 17, No. 5, 239–247 (2002).CrossRefPubMedGoogle Scholar
  25. 25.
    A. D. Lopez, C. D. Mathers, M. Ezzati, et al., “Global and regional burden of disease and risk factor, 2001: systematic analysis of population health data,” Lancet, 367, 1747–1757 (2006).CrossRefPubMedGoogle Scholar
  26. 26.
    A. McIntyre, A. Gendron, and A. McIntyre, “Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study,” Depress. Anxiety, 24, No. 7, 487–494 (2007).CrossRefPubMedGoogle Scholar
  27. 27.
    M. J. Millan, M. Brocco, A. Gobert, et al., “Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade,” Psychopharmacology, 177, No. 4, 448–458 (2005).CrossRefPubMedGoogle Scholar
  28. 28.
    N. Mor and D. Haran, “Cognitive-behavioral therapy for depression,” Isr. J. Psychiatry Relat. Sci., 46, No. 4, 269–273 (2009).PubMedGoogle Scholar
  29. 29.
    J. P. Olié and S. Kasper, “Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder,” Int. J. Neuropsychopharmacol., 10, No. 5, 661–673 (2007).PubMedGoogle Scholar
  30. 30.
    M. H. Pollack, “Comorbid anxiety and depression,” J. Clin. Psychiatry, 66, No. 8, 22–29 (2005).PubMedGoogle Scholar
  31. 31.
    A. Qaseem, V. Snow, T. D. Denberg, et al., “Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians,” Ann. Intern. Med., 149, No. 10, 725–733 (2008).CrossRefPubMedGoogle Scholar
  32. 32.
    M. A. Quera-Salva, P. Lemoine, and C. Guilleminault, “Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients,” Hum. Psychopharmacol., 25, No. 3, 222–229 (2010).CrossRefPubMedGoogle Scholar
  33. 33.
    S. M. Stahl, M. Fava, M. H. Trivedi, et al., “Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial,” J. Clin. Psychiatry, 71, No. 5, 616–626 (2010).CrossRefPubMedGoogle Scholar
  34. 34.
    D. J. Stein, A. Ahokas, C. Albarran, et al., “Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study,” J. Clin. Psychiatry, 73, No. 7, 1002–108 (2012).CrossRefPubMedGoogle Scholar
  35. 35.
    D. J. Stein, A. A. Ahokas, and C. de Bodinat, “Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study,” J. Clin. Psychopharmacol., 28, No. 5, 561–566 (2008).CrossRefPubMedGoogle Scholar
  36. 36.
    F. Wedegaertner, S. Arnhold-Kerri, N. A. Sitgtaro, et al., “Depression- and anxiety-related sick leave and the risk of permanent disability and mortality in the working population in Germany: a cohort study,” BMC Public Health, 13, No. 1, 145 (2013).CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    S. Wetzler and M. M. Katz, “Problems with the differentiation of anxiety and depression,” J. Psychiat. Res., 23,. No. 1, 1–12 (1989).CrossRefPubMedGoogle Scholar
  38. 38.
    A. S. Young, R. Klap, R. Shoai, et al., “Persistent depression and anxiety in the United States: prevalence and quality of care,” Psychiatr. Serv., 59, No. 12, 1391–1398 (2008).CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    J. Zajecka, A. Schatzberg, S. Stahl, et al., “Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial,” J. Clin. Psychopharmacol., 30, No. 2, 135–144 (2010).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • A. A. Pribytkov
    • 1
  • N. B. Panova
    • 2
  • Yu. V. Popova
    • 2
  • K. G. Emtsov
    • 3
  1. 1.Penza Institute of Advanced MedicalRussian Ministry of HealthPenzaRussia
  2. 2.Evgrafov Regional Psychiatric HospitalPenzaRussia
  3. 3.Togliatti Psychoneurological DispensaryTogliattiRussia

Personalised recommendations